Presentation is loading. Please wait.

Presentation is loading. Please wait.

Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel  Makoto Kawaishi, MD, Yutaka Fujiwara, MD,

PublishAmelia Garrett Modified over 6 years ago

Similar presentations

Presentation on theme: "Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel  Makoto Kawaishi, MD, Yutaka Fujiwara, MD,"— Presentation transcript:

1 Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel  Makoto Kawaishi, MD, Yutaka Fujiwara, MD, Tomoya Fukui, MD, Terufumi Kato, MD, Kazuhiko Yamada, MD, Yuichiro Ohe, MD, PhD, Hideo Kunitoh, MD, PhD, Ikuo Sekine, MD, PhD, Noboru Yamamoto, MD, PhD, Hiroshi Nokihara, MD, PhD, Takeshi Watabe, PhD, Yuji Shimoda, PhD, Tokuzo Arao, MD, PhD, Kazuto Nishio, MD, PhD, Tomohide Tamura, MD, Fumiaki Koizumi, MD, PhD  Journal of Thoracic Oncology  Volume 4, Issue 2, Pages (February 2009) DOI: /JTO.0b013e d Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Scatter plot analysis to determine the correlation between the number of circulating endothelial cell (CEC) and estimated tumor volume (ETV). ETV is calculated with computed tomography (CT) examination. Case 21 is not included. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e d) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Circulating endothelial cell (CEC) levels during the first course of CDDP plus paclitaxel chemotherapy. *p < 0.05 versus values at baseline. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e d) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 A, Comparison of circulating endothelial cell (CEC) amount at baseline in non-small cell lung cancer (NSCLC) patients with different clinical responses to CBDCA plus paclitaxel chemotherapy. *p < 0.05 versus values of patients with progressive disease (PD). Case 21 is not included. B, Relative change in CEC amount in patients with partial response (PR), stable disease (SD), and PD. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e d) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Progression-free-survival according to circulating endothelial cell (CEC) count at baseline. The median duration of progression-free survival was greater in patients whose CEC count exceeded 400 (median, 244 days) than in patients whose CEC count was less than 400 (69 days). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e d) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel  Makoto Kawaishi, MD, Yutaka Fujiwara, MD,"

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer  Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,

Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer  Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,
Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,
Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small.

Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small.
A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors  Tomohide Tamura, MD, Hironobu Minami, MD, Yasuhide Yamada,

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors  Tomohide Tamura, MD, Hironobu Minami, MD, Yasuhide Yamada,
Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non- small Cell Lung Cancer: A Phase II Study  Kaoru Kubota, MD, PhD,

Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non- small Cell Lung Cancer: A Phase II Study  Kaoru Kubota, MD, PhD,
Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non–Small-Cell.

Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non–Small-Cell.

Similar presentations

Ads by Google